Portfoliotracker

Rani Therapeutics Holdings, Inc.

RANI · NASDAQCM · Healthcare Biotechnology 2/100 E

0,540 $
▲ +0,014 (+2,66 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:40
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score2 / 100 Market cap101 mil. $ P/E– Forward P/E-2,8 P/S20,7 P/B2,6 EV/EBITDA– Dividend yield– FCF yield-20,12 % EPS-0,07 $ Net margin0,0 % Return on equity-233,6 % Beta– Debt / equity0,08
52-week range 0,50 to 1,99
3-month average volume0,6 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Employees
69
Country
United States
Fiscal year end
31. 12.
Data since
30. 7. 2021

Explore further

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account